

# PROMOGRAN PRISMA™ MATRIX

## Has What it Takes



# PROMOGRAN PRISMA™ MATRIX SUPPORTS GRANULATION AND EPITHELIAZATION

In a 14-week RCT comparing **PROMOGRAN PRISMA®** (n=25), with Control (n=15), the number of patients withdrawn from the study due to infection was

SIGNIFICANTLY GREATER IN THE CONTROL GROUP

**VS. 31%** (p=0.012)<sup>1</sup> (n=40)

SIGNIFICANTLY GREATER RATE OF WOUND HEALING AT WEEK FOUR

**79% VS. 43%** for the standard of care

(Improved defined as >50% reduction in wound size)<sup>1</sup>





#### Don't Wait—Initiate

Choosing the right dressing has been proven in a PROMOGRAN™ Matrix 6-week RCT to dramatically impact healing time.

IN A 6-WEEK RCT STUDY

of pressure ulcer wounds completely healed in the

PROMOGRAN™ MATRIX GROUP (n=40)

compared to only 70% in the Control group<sup>2\*</sup> (n=40)

shorter mean time to complete healing in the

PROMOGRAN™ MATRIX GROUP

than the Control group (360 days overall hospitalization vs 1,164 days)<sup>2</sup>

#### Better results with fewer dressing changes

A 12-week RCT of patients with venous leg ulcers (n=73), **47.6% more wounds** (62% vs 42%, p=0.0797) healed or improved<sup>†</sup> in the PROMOGRAN™ Matrix + compression group than in the Control group (non-adherent dressing + compression). A significant reduction in wound area was achieved in the PROMOGRAN™ Matrix + compression group compared to Control (54.4% vs 36.5%, p<0.0001).³ (n=73)

## ACELITY LEADS COLLAGEN INNOVATION FOR EVERY LEVEL OF NEED



has gel forming properties with structural support



### PROMOGRAN™ **Matrix COLLAGEN** & ORC

efficacy supported by a body of clinical evidence, including RCT data<sup>1</sup>



## PROMOGRAN PRISMA™ Matrix has 2X THE AMOUNT OF COLLAGEN/ORC plus the **ADDITION OF SILVER**

a known antimicrobial agent

## To learn more contact your ACELITY representative at 800-275-4524 or visit acelity.com

PROMOGRAN™ Matrix Wound Dressing (n=40) vs Control (moist wound healing—vaseline gauze and hydropolymer patch; n=40) <sup>†</sup>≥ 50% wound area reduction at week 12

#### REFERENCES

- 1. Gottrup F, et al. Randomized controlled trial on collagen/oxidized regenerated cellulose/silver treatment. Wound Repair Regen. 2013; 21(2):216-225. doi: 10.111/wrr.12020.
- 2. Nisi G, et al. Use of a protease modulating matrix in the treatment of pressure sores. Chir Ital. 2005; 57(4):465-468.
- 3. Vin F, Teot L, Meaume S. The healing properties of collagen/ORC in venous leg ulcers. J Wound Care. 2002; 11(9):335-341.

Follow local institutional protocols for infection control and waste disposal procedures. Local protocols should be based on the applicable federal, state and/or local government environmental regulations.

NOTE: Specific indications, contraindications, warnings, precautions and safety information may exist for Systagenix products. Please consult a healthcare provider and product instructions for use prior to application. Rx only.

Copyright 2017 Systagenix Wound Managment, Limited. All rights reserved. All trademarks designated herein are proprietary to Systagenix Wound Management, Limited, its affiliates and/or licensors. LIT# 29-A-326 • PRA000740-R0-US, EN (05/17)



